



**FOR IMMEDIATE RELEASE**

May 4, 2022

Listed Company Name: Eisai Co., Ltd.  
 Representative: Haruo Naito  
 Representative Corporate Officer and CEO  
 Securities Code: 4523  
 Stock Exchange Listings: Prime Market of the Tokyo Stock Exchange  
 Inquiries: Sayoko Sasaki  
 Vice President, Chief IR Officer  
 Stakeholder Communications  
 Phone +81-3-3817-5120

**Notification Regarding Revision of Consolidated Financial Forecasts (IFRS) for the Fiscal Year Ended March 31, 2022**

Eisai Co., Ltd. (“the Company”) announced today that based on the impact of National Coverage Determination (NCD) for the anti-amyloid-beta antibody aducanumab (product name in the U.S.: ADUHELM) issued by the U.S. Centers for Medicare & Medicaid Services’ (CMS) on April 7, 2022 and other factors, the Company has revised its consolidated financial forecasts for the fiscal year ended March 31, 2022 (April 1, 2021 to March 31, 2022) previously announced on November 1, 2021, as follows.

1. Revised consolidated financial forecasts for the fiscal year ended March 31, 2022 (April 1, 2021 to March 31, 2022)

(Unit: Millions of yen, unless otherwise noted.)

	Revenue	Operating profit	Profit before income taxes	Profit for the period	Profit attributable to owners of the parent	Basic earnings per share
Previously announced forecast (A) (November 1, 2021)	730,000	78,000	78,500	61,000	60,500	211.00 yen
Currently revised forecast (B)	756,000	53,500	54,500	45,500	48,000	167.30 yen
Change in amount (B - A)	26,000	-24,500	-24,000	-15,500	-12,500	
Percentage of change (%)	3.6%	-31.4%	-30.6%	-25.4%	-20.7%	
(Reference) Business results for the fiscal year ended March 31, 2021	645,952	51,766	52,551	42,483	42,119	146.95 yen

## 2. Reason for revision of the consolidated financial forecasts

Revenue is estimated to be ¥756.0 billion, up ¥26.0 billion from the previously announced forecasts, based on product performance and foreign exchange trends.

Receiving Biogen Inc.'s updated demand forecast for aducanumab based on the NCD by CMS, the Company will record an impairment loss of ¥8.0 billion in cost of sales after reevaluating sales rights of aducanumab recorded by the Company as well as ¥16.5 billion in SG&A expenses as the Company's share of the write-down of inventory recorded by Biogen Inc. As a result, operating profit is estimated to be ¥53.5 billion, down ¥24.5 billion from the previously announced forecast. Accordingly, profit attributable to owners of the parent is expected to be ¥48.0 billion, down ¥12.5 billion from the previously announced forecast. There are no changes to the total dividend for the fiscal year which is set at ¥160 per share (same amount as the previous fiscal year) with the fiscal year-end dividend is planned to be ¥80 per share.

\*Please note that the above-mentioned forecasts were made based on information available as of May 3, 2022. Actual results will be disclosed in the earnings announcement on May 13, 2022.

\*\*\*